Alx Competitors
| ALXO Stock | USD 1.87 0.19 11.31% |
Alx Oncology vs Sutro Biopharma Correlation
Average diversification
The correlation between Alx Oncology Holdings and STRO is 0.11 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Alx Oncology Holdings and STRO in the same portfolio, assuming nothing else is changed.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Alx Oncology's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Alx Oncology Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Alx Oncology and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Alx and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Alx Oncology Holdings does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Alx Stock performing well and Alx Oncology Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Alx Oncology's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| DTIL | 3.06 | (1.12) | 0.00 | (1.91) | 0.00 | 4.71 | 15.28 | |||
| RPTX | 2.16 | 0.56 | 0.24 | 1.81 | 1.47 | 3.95 | 35.71 | |||
| GUTS | 4.94 | (0.72) | 0.00 | (1.71) | 0.00 | 11.89 | 85.71 | |||
| ATYR | 3.81 | 0.10 | 0.02 | 0.23 | 3.77 | 8.45 | 23.34 | |||
| ARTV | 6.61 | 0.47 | 0.06 | 0.30 | 7.70 | 8.00 | 118.69 | |||
| ADVM | 3.39 | 0.43 | 0.10 | 0.87 | 3.70 | 10.34 | 40.97 | |||
| BMEA | 4.22 | (0.26) | 0.00 | (0.18) | 0.00 | 9.38 | 28.51 | |||
| MGX | 3.03 | (0.69) | 0.00 | (0.31) | 0.00 | 6.02 | 19.55 | |||
| IMUX | 3.44 | (0.26) | 0.00 | (0.15) | 0.00 | 9.43 | 21.44 | |||
| STRO | 4.98 | 0.66 | 0.12 | 0.56 | 5.24 | 11.76 | 27.28 |
Cross Equities Net Income Analysis
Compare Alx Oncology Holdings and related stocks such as Precision BioSciences, Repare Therapeutics, and Fractyl Health Common Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DTIL | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (21.1 M) | (46 M) | (92.9 M) | (109 M) | (30.6 M) | (111.6 M) | (61.3 M) | 7.2 M | 6.5 M | 6.8 M |
| RPTX | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (14.3 M) | (27.2 M) | (53.4 M) | (106.9 M) | (29 M) | (93.8 M) | (84.7 M) | (76.2 M) | (80 M) |
| GUTS | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.5 M) | (38.7 M) | (46.5 M) | (77.1 M) | (68.7 M) | (68.7 M) | (61.8 M) | (64.9 M) |
| ATYR | (17.6 M) | (17.6 M) | (17.6 M) | (20 M) | (24.4 M) | (48 M) | (57.9 M) | (48.2 M) | (34.5 M) | (23.6 M) | (16.2 M) | (33.8 M) | (45.3 M) | (50.4 M) | (64 M) | (57.6 M) | (60.5 M) |
| ARTV | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (71.8 M) | (58.4 M) | (27.7 M) | (58.5 M) | (52.6 M) | (55.3 M) |
| BMEA | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (5.3 M) | (41.2 M) | (80 M) | (117.3 M) | (138.4 M) | (124.6 M) | (118.4 M) |
| MGX | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (43.6 M) | (68.3 M) | (78.1 M) | (78.1 M) | (70.3 M) | (73.8 M) |
| IMUX | (5.9 M) | (5.9 M) | (6.7 M) | (32.7 M) | (47.7 M) | (52 M) | (41 M) | (52.1 M) | (41.5 M) | (34.8 M) | (44 M) | (92.8 M) | (120.4 M) | (93.6 M) | (100.5 M) | (90.5 M) | (85.9 M) |
| STRO | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | (19.7 M) | (35.3 M) | (55.7 M) | (32.1 M) | (105.5 M) | (119.2 M) | (106.8 M) | (227.5 M) | (204.7 M) | (194.5 M) |
Alx Oncology Holdings and related stocks such as Precision BioSciences, Repare Therapeutics, and Fractyl Health Common Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Alx Oncology Holdings financial statement analysis. It represents the amount of money remaining after all of Alx Oncology Holdings operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Alx Oncology Competitive Analysis
The better you understand Alx Oncology competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Alx Oncology's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Alx Oncology's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Alx Oncology Competition Performance Charts
Five steps to successful analysis of Alx Oncology Competition
Alx Oncology's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Alx Oncology Holdings in relation to its competition. Alx Oncology's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Alx Oncology in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Alx Oncology's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Alx Oncology Holdings, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Alx Oncology position
In addition to having Alx Oncology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Large Cap ETFs Thematic Idea Now
Large Cap ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Large Cap ETFs theme has 896 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Large Cap ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Alx Oncology Correlation with its peers. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Will Biotechnology sector continue expanding? Could Alx diversify its offerings? Factors like these will boost the valuation of Alx Oncology. If investors know Alx will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Alx Oncology data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Alx Oncology Holdings is measured differently than its book value, which is the value of Alx that is recorded on the company's balance sheet. Investors also form their own opinion of Alx Oncology's value that differs from its market value or its book value, called intrinsic value, which is Alx Oncology's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Alx Oncology's market value can be influenced by many factors that don't directly affect Alx Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Alx Oncology's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Alx Oncology represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Alx Oncology's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.